| Literature DB >> 33203044 |
Ivan Liakh1,2, Tomasz Sledzinski1, Lukasz Kaska3, Paulina Mozolewska1, Adriana Mika1,4.
Abstract
Obesity is associated with alterations in the composition and amounts of lipids. Lipids have over 1.7 million representatives. Most lipid groups differ in composition, properties and chemical structure. These small molecules control various metabolic pathways, determine the metabolism of other compounds and are substrates for the syntheses of different derivatives. Recently, lipidomics has become an important branch of medical/clinical sciences similar to proteomics and genomics. Due to the much higher lipid accumulation in obese patients and many alterations in the compositions of various groups of lipids, the methods used for sample preparations for lipidomic studies of samples from obese subjects sometimes have to be modified. Appropriate sample preparation methods allow for the identification of a wide range of analytes by advanced analytical methods, including mass spectrometry. This is especially the case in studies with obese subjects, as the amounts of some lipids are much higher, others are present in trace amounts, and obese subjects have some specific alterations of the lipid profile. As a result, it is best to use a method previously tested on samples from obese subjects. However, most of these methods can be also used in healthy, nonobese subjects or patients with other dyslipidemias. This review is an overview of sample preparation methods for analysis as one of the major critical steps in the overall analytical procedure.Entities:
Keywords: biological samples; lipids; liquid–liquid extraction; obesity; protein precipitation; sample preparation; solid-phase extraction
Mesh:
Substances:
Year: 2020 PMID: 33203044 PMCID: PMC7696154 DOI: 10.3390/molecules25225307
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Lipid alterations in obesity. Lipids in red are elevated in obesity, and lipids in green are reduced. BCAA—branched chain amino acids; BCFA—branched chain fatty acids; DAG—diacylglycerols; FFA—free fatty acids; HDL—high density lipoproteins; LDL—low density lipoproteins; LPP—lipid peroxidation products; MUFA—monounsaturated fatty acids; OCFA—odd chain fatty acids; SFA—saturated fatty acids; PUFA—polyunsaturated fatty acids; TAG—triacyclglycerols.
Sample preparation methods for lipidomics approaches used in the studies of obesity.
| Lipid Class(es) | Matrix | Sample Preparation Method | Analysis Method | References | ||
|---|---|---|---|---|---|---|
| Pre-Preparation | Extraction Method | Derivatization Step | ||||
| PL | Plasma | - | modified Folch method | sodium methoxide—FAME | GC | Blewett et al. [ |
| FFA, TAG | Plasma | - | Bligh and Dyer’s method | 14% BF3 - MeOH - FAME | GC-MS | Choromańska et al. [ |
| LPAs | Plasma | - | hydrochloric acid + MeOH/chloroform (2:1) | - | ESI-MS –MS | Yoon et al. [ |
| SM | Plasma | MeOH | modified Matyash method | - | LC-MS/MS | Im et al. [ |
| lipidomic profile (328 lipid species from 24 lipid classes: dhCer, Cer. MHC, DHC, THC, GM3, SM, PC, PC(0), PC(P), LPC, PE, PE(0), PE(P), LPE, PI, LPI, PS, PG, CE, COH, DG, TG) | Plasma | MeOH | chloroform/MeOH (2:1) | - | LC ESI-MS/MS | Wang et al. [ |
| untargeted metabolomics analysis /lipidomic profile? (515 metabolites) | Serum | - | ACN: isopropanol: water (3:3:2) | MSTFA + MTBSTFA | 2D GC-ToF-MS | Misra et al. [ |
| lipidomic profile (143 lipid species from lipid classes: FA, FFA, PC, PE, PI, PS, PG, LPC, LPA, SM) | Plasma | - | MeOH/n-hexane (4:1) | acetyl chloride + 6% K2CO3 | GC- FID/MS | Wang et al. [ |
| sterols | Serum | MeOH | solid-phase extraction (hybrid solid-phase extraction-precipitation (H-PPT) cartridge) | MSTFA/ammonium iodide (NH 4 I)/dithioerythritol (DTE) (500:4:2) | GC-MS | Cho et al. [ |
| total FAs + circulating PL, TG | Serum | - | chloroform/MeOH (2:1) | methylation (100 °C; 1.5 h) | GC- FID | Perreault et al. [ |
| FFA, TAG, PL | Serum | - | Folch method | 10% BF3 - MeOH | GC–MS | Śledziński et al. [ |
| SFA, MUFAs, PUFAs | Plasma | - | MeOH | acetyl chloride + 6% K2CO3 | GC-MS | Kang et al. [ |
| MCFAs, NEFAs | Serum | MeOH | - | 10M KOH in MeOH + 24 N H2SO4 | GC-MS | Wijayatunga et al. [ |
| PUFAs | Plasma | ACN/37% hydrochloric acid (4:1) | n-hexane | - | LC-MS/MS | Aslan et al. [ |
| MUFAs, PUFAs, OCFAs | Serum | ACN | chloroform/MeOH (2:1) | - | UHPLC-MS | Ma et al. [ |
| PUFAs | Plasma | MeOH | - | acetyl chloride + 6% K2CO3 | LC-MS | Itariu et al. [ |
| NEFAs | Plasma | - | Dole extraction | - | LC-MS | Nemati et al. [ |
| MUFAs, PUFAs, SFA | Serum | - | chloroform/MeOH (2:1) | HCl in MeOH | GLC-FID | Lin et al. [ |
| FAs, bile acids (BA), steroids, LPL, glycerolipids, cholesterol esters, SPL, PL | Serum | For FAs, bile acids (BA), steroids and LPL - MeOH | For glycerolipids, cholesterol esters, sphingolipids and phospholipids - NaCl + chloroform/MeOH (2:1) | - | UPLC-MS | Ramos-Molina et al. [ |
| Serum | - | chloroform/MeOH (2:1) | - | UHPLC-MS | Ramos-Molina et al. [ | |
| FAHFAs | Serum | MeOH | solid-phase extraction (hysphere C8 cartridges) | - | LC-MS/MS | López-Bascón et al. [ |
| SCFAs | Plasma | MeOH | dichloromethane | 0.1 M O-benzylhydroxylamine (O-BHA) in MeOH and 0.25 M N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC) in MeOH | LC-MS/MS | Zeng and Cao [ |
| MAG, FAE, oxFAE, oxMAG, FA, oxFA, DAG, TAG, PE, PI, NAPE, LNAPE, PC | Plasma | - | Chloroform | - | LC/MS | Astarita et al. [ |
| endocannabinoids | Plasma | - | Chloroform | - | UPLC-MS/MS | Argueta et al. [ |
| endocannabinoids | Plasma | - | Chloroform | - | UPLC-MS/MS | Perez et al. [ |
| oxylipins | Serum | - | solid-phase extraction (C18 cartridges) | - | online SPE–LC–MS/MS | Ferreiro-Vera et al. [ |
| nonesterified PUFAs and oxylipins | Plasma | MeOH + formic acid | solid-phase extraction (Strata-X) | - | UHPLC-MS/MS | Pickens et al. [ |
| oxylipins, endocannabinoid, Cer | Serum | IPA with 10 mM ammonium formate + 1% formic acid | - | - | UPLC-MS/MS | Hernandez-Carretero et al. [ |
| endocannabinoids | Serum | acetones + Tris buffer (50 mM, pH 8.0) | chloroform/MeOH (2:1) | - | LC-MS/MS | Azar et al. [ |
| unesterified oxylipins, endocannabinoids | Plasma | MeOH/ACN (1:1) | solid-phase extraction (BEH C18 colum) | - | UPLC-MS/MS | Fan et al. [ |
| Cer | Plasma | - | Bligh and Dyer method | - | UPLC-MS/MS | León-Aguilar et al. [ |
| Cer, SM | Serum | - | chloroform/MeOH (2:1) | - | (UFLC)-MS/MS | Özer et al. were [ |
| FA | Adipose tissue | - | MeOH/chloroform (2:1) | 10 % BF3 - MeOH | GC–MS | Roberts et al. [ |
| acylcarnitines | Adipose tissue | - | MeOH/chloroform (2:1) | - | LC–MS | Roberts et al. [ |
| SFA, MUFAs, TFA, PUFAs | Adipose tissue | - | sodium methoxide | GC–FID/MS analysis | Kunešová et al. [ | |
| FAHFAs | Adipose tissue | - | MTBE/MeOH/water | - | UPLC-MS/MS | Hu et al. [ |
| oxylipins | Adipose tissue | MeOH | RapidTrace Biotage | - | LC-MS-MS | Okada et al. [ |
| TAG | Adipose tissue | - | Bligh and Dyer method | - | LC-MS | Al-Sulaiti et al. [ |
| more than 300 lipid species from lipid classes: CL, Cer, ST. HexCer, LPA, LPC, LPE, LPG, LPI, LPS, SM, TAG, CE, DAG, PA, PC, PE, PG, PI, PS | Adipose tissue | - | two-step chloroform/MeOH extraction | - | MS | Grzybek et al. [ |
| TAG, MAG, DAG, LysoPC, PC, LysoPE, PE, Cer, SM, PI, PS, FA | Adipose tissue | - | modified Folch method | - | LC-MS | Tomášová et al. [ |
| oxysterols, Cer, endocannabinoids | Adipose tissue | - | dichloromethane/MeOH/water (8:4:2) + solid-phase extraction (C18 colum) | - | LC-MS | Mutemberezi et al. [ |
| OxPL | Adipose tissue | - | chloroform/MeOH (3:1) + BHT | - | LC-MS | Serbulea et al. [ |
| MAG, DAG, TAG, NL, Cer, FFA, GSPL, SM | Liver | - | Folch extraction | 10% BF3 - MeOH | GC-MS | Pakiet et al. [ |
| STA, MUFA, PUFA | HepG2 cells | - | chloroform/MeOH (2:1) + BHT | hexane + 0.05% BHT | GC- FID | Lytle et al. [ |
| Cer, SM, GPCho, GPEtn, GPSer, GPA, GPGro, DG, TG | Liver | - | chloroform/MeOH (2:1) | - | UPLC-MS | Yetukuri et al. [ |
| LPL (LPS, LPA, LPI, LPG, LPC, LPE) | Liver | 4% formic acids in MeOH | modified method of Bligh and Dyer + solid-phase extraction (HybridSPE cartridge) | - | ESI-MS | Wang et al. [ |
| SFA, MUFA, PUFA | Liver | - | chloroform:MeOH (2:1) plus 1 mM BHT | 1% H2SO4 in MeOH | GC–FID | Garcia-Yaramillo et al. [ |
| PUFA, PUFA-derived oxylipins | Liver | MeOH | solid-phase extraction (Strata-X) | - | targeted UPLC-TOF-MS/MS | Garcia-Yaramillo et al. [ |
| DAG, TAG, PC, PS, PI, PG, PE, LPL, SM | Liver | - | methylene chloride/IPA/MeOH (25:10:65) | - | untargeted UPLC-TOF-MS/MS | Garcia-Yaramillo et al. [ |
| DAG, Cer | Liver | - | Folch method + solid-phase extraction (Sep Pak Diol Cartridges) | - | LC-MS/MS | Preuss et al. [ |
| Brain | - | IPA/water/ethyl acetate (30:10:60) | - | LC-MS | Yang et al. [ | |
| non-esterified oxylipins, endocannabinoids, PUFAs | Brain | MeOH | MTBE | - | UHPLC-QTOF-MS | Rutkowsky et al. [ |
| Cer, DG, ClcCer, LPC, PC, PE, FA, PI, SM | Brain | - | MeOH/ethyl acetate | - | CSH-ESI QTOF MS/MS | Rutkowsky et al. [ |
| endocannabinoid | Brain | - | chloroform/MeOH/50 mM Tris HCl (2:1:1) | MSTFA + 1% trimethylchlorosylane | GC-MS | Kirkham et al. [ |
| SFA, MUFA, PUFA | Skeletal muscle | - | Bligh and Dyer method | anhydrous MeOH containing 2.5 M HCl (100 °С; 2 h) | GC-FID | Gudbrandsen et al. [ |
| FFA, DAG, TAG, PL | Skeletal muscle | - | chloroform/MeOH (2:1) | 14% BF3 - MeOH | GC-MS | Van Hees et al. [ |
| CE, TAG, GPL | Skeletal muscle | - | for CE, TAG and GPL fractions - tert-butyl methyl ether (90%, tert-BME) and MeOH; for FFA fraction chloroform/MeOH (2:1) + solid phase extraction | 2 M sodium methoxide solution | GC-MS | Laurentius et al. [ |
| LPC, LPE, PI, PG, Cer, PC, PE, PS, TG, HexCer, SM | Skeletal muscle | - | two-stage extraction method using MTBE/MeOH | - | nUHPLC-ESI-MS/MS | Eum et al. [ |
| DAG, Cer, acyl-CoA | Heart | - | Bligh and Dyer method | - | HPLC-UV | Harmancey et al. [ |
| sphingolipids | Heart | - | MeOH/chloroform | - | LC-MS/MS | Merrill et al. [ |
| SFA, MUFA, PUFA | Heart | - | chloroform/MeOH (2:1) + solid-phase extraction (Strata) | 10% BF3—MeOH | GC–MS | Pakiet et al. [ |
| SM, PC, PE, PG, PI, PS | Urine | - | ACQUITY UPLC HSS-T3 C18 column | - | UPLC-QTOF-MS/MS | Feng et al. [ |
| Cholesterol, 7-ketocholesterol | Saliva | - | for cholesterol and 7-ketocholesterol chloroform/MeOH (2:1); for 25-hydroxyvitamins D2 and D3 MeOH/IPA | - | HPLC-DAD | Araujo and Santos [ |
| FFA, PI, PC, LPC, PS, PE, TG | Follicular fluid and serum | - | IPA/acetonitrile/water (3:3:2) or MTBE | MSTFA + 1% TMCS | GC-MS | Ruebel et al. [ |
| FFA, PI, PC, LPC, PE, PS | Follicular fluid and serum | - | IPA/acetonitrile/water (3:3:2) or MTBE | - | untargeted CSH-ESI QTOF MS/MS | Ruebel et al. [ |
| SCFAs | Faecal samples | - | - | CTC Combipal 3 autosampler in HS/SPME mode equipped with a gray fibe | GC-MS | Cuesta-Zuluaga et al. [ |
2D GC-ToF-MS: two-dimensional gas chromatography time-of-flight mass spectrometer; ESI-MS–MS: turbo electrospray ionization tandem mass spectrometry; GC- FID/MS: gas chromatography-flame ionization detector-mass spectrometer; GC-FID: gas chromatography-flame ionization detection; GLC-FID: gas liquid chromatography-flame ionization detector; HPLC-UV: high-performance liquid chromatography with UV-detection; LC-HRMS/MS: liquid-chromatography high-resolution tandem mass spectrometry; LC-MS-MS liquid chromatography with tandem mass spectrometry; nUHPLC-ESI-MS/MS: nanoflow ultrahigh performance liquid chromatography with tandem mass spectrometry; UHPLC/Q-TOF-MS: ultra-high performance liquid chromatography-quadrupole time-of-flight mass spectrometry; UPLC-QTOF-MS: ultra-performance liquid chromatography quadrupole time-of-flight mass spectrometry; UPLC-TOF-MS/MS: ultra-high performance liquid chromatography coupled to a Triple time-of-flight mass spectrometer; PL: phospholipids; FFA: free fatty acids; TAG: triacylglycerol; LPA: lysophosphatidic acid; SM: sphingomyelin; dhCer: dihydroceramide; Cer: ceramides; MHC: monohexosylceramide; DHC: dihexosylceramide; THC: trihexosylceramide; GM3:ganglioside; PC: phosphatidylcholine; PC(0): alkylphosphatidylcholine; PC(P): phosphatidylcholine plasmalogen; LPC: lysophosphatidylcholine; PE: phosphatidylethanolamine, PE(0): akylphosphatidylethanolamine; PE(P): phosphatidylethanolamine plasmalogen; LPE: lysophosphatidylethanolamine; PI: phosphatidylinositol; LPI: lysophosphatidylinositol, PS: phosphatidylserine; PG: phosphatidylglycerol; CE: chofesterol ester; COH: free cholesterol; DG: diacylglycerol; TG: triacylglycerol; FA: fatty acid; SFA: saturated fatty acid; MUFAs: monounsaturated fatty acids; PUFAs: polyunsaturated fatty acids; NEFAs: non-esterified fatty acids; OCFAs: odd-carbon fatty acids; SPL: sphingolipids; FAHFAs: fatty acid esters of hydroxy fatty acids; SCFAs: short-chain fatty acids; MAG: monoacylglycerol; FAE: fatty-acid ethanolamides; oxFA: oxygenated FAE; oxMAG: oxygenated MAG; oxFA: oxygenated fatty acids; NAPE: N-acyl-phosphatidylethanolamine; LNAPE: lyso-NAPE; TFA: trans fatty acids; CL: cardiolipin; ST: cholesterol; HexCer: hexosylceramide; LPG: lysophosphatidylglycerol; LPI: lysophosphatidylinositol; LPS: lysophosphatidylserine; PA: Phosphate; LysoPC: Lysophosphatidylcholines; LysoPE: Lysophosphatidylethanolamines; OxPL: oxidized phospholipids; NL: neutral lipids; GSPL: glycosphingolipids; GPCho: diacylglycerophosphocholine; GPEtn: glycerophosphoethanolamines; GPSer: glycerophosphoserine; GPGro: Glycerophosphoglycerol; GlcCer: Glucosylceramides; Acyl:CoA:dihydroxyacetone phosphate acyltransferase; CSH-ESI QTOF MS/MS: charged-surface hybrid column-electrospray ionization quadrupole time-of-flight tandem mass spectrometry.
Figure 2Lipid analysis in diagnostic laboratory vs. advanced lipidomic studies.